NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free QNRX Stock Alerts $0.77 -0.02 (-2.52%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.76▼$0.7950-Day Range$0.63▼$2.9052-Week Range$0.60▼$12.00Volume68,615 shsAverage Volume438,127 shsMarket Capitalization$2.85 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Quoin Pharmaceuticals alerts: Email Address Quoin Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside417.7% Upside$4.00 Price TargetShort InterestHealthy0.26% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 stars 3.5 Analyst's Opinion Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageQuoin Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Quoin Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.26% of the outstanding shares of Quoin Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently decreased by 37.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QNRX. Previous Next 2.3 News and Social Media Coverage News SentimentQuoin Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Quoin Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest11 people have searched for QNRX on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Quoin Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Quoin Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Quoin Pharmaceuticals Stock (NASDAQ:QNRX)Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Read More QNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QNRX Stock News HeadlinesMay 9, 2024 | msn.comQuoin Pharmaceuticals Non-GAAP EPS of -$1.11 misses by $0.70May 9, 2024 | finance.yahoo.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial ResultsMay 10, 2024 | Stansberry Research (Ad)Biggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."May 9, 2024 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial ResultsMay 8, 2024 | americanbankingnews.comQuoin Pharmaceuticals (QNRX) to Release Earnings on ThursdayMay 2, 2024 | globenewswire.comQuoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024March 16, 2024 | seekingalpha.comQuoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comMaxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To KnowMay 10, 2024 | Stansberry Research (Ad)Biggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."March 15, 2024 | finance.yahoo.comQuoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsMarch 14, 2024 | benzinga.comQuoin Pharmaceuticals: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial ResultsMarch 7, 2024 | msn.comWhy Quoin Pharmaceuticals (QNRX) Shares Are NosedivingMarch 7, 2024 | globenewswire.comQuoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ETMarch 6, 2024 | finance.yahoo.comQNRX: Potential Pool of Study Participants Expands; Financial Position StrengthsMarch 5, 2024 | seekingalpha.comQTI, RNLX and MTC among pre-market losersMarch 5, 2024 | msn.comWhy Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?March 5, 2024 | finance.yahoo.comQuoin Pharmaceuticals Announces Pricing of $6.5 Million Public OfferingMarch 4, 2024 | marketwatch.comQuoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 TrialMarch 4, 2024 | markets.businessinsider.comQuoin Pharma Says FDA Clears Recruitment Of Teen Subjects For Two Ongoing Clinical Trials For QRX003March 4, 2024 | msn.comWhy Quoin Pharmaceutical Stock Is SoaringDecember 15, 2023 | markets.businessinsider.comBuy Rating for Quoin Pharmaceuticals Amid Promising Netherton Syndrome Drug ProspectsDecember 13, 2023 | morningstar.comQuoin Pharmaceuticals Ltd ADRDecember 13, 2023 | finanznachrichten.deQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton SyndromeDecember 13, 2023 | markets.businessinsider.comFDA Clears Quoin Pharma's Protocol Amendments For QRX003 Trials In Netherton Syndrome TreatmentNovember 13, 2023 | finance.yahoo.comQNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory ApprovalSee More Headlines Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today5/10/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:QNRX CUSIPN/A CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+417.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($10.2416) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-105.09% Return on Assets-55.69% Debt Debt-to-Equity RatioN/A Current Ratio3.15 Quick Ratio3.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.74 per share Price / Book0.13Miscellaneous Outstanding Shares3,690,000Free Float3,564,000Market Cap$2.85 million OptionableNot Optionable Beta1.85 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Michael Myers Ph.D. (Age 62)Co-Founder, CEO & Chairman Comp: $661.8kMs. Denise Carter (Age 55)Co-Founder, COO & Director Comp: $537.8kMr. Gordon Bruce Dunn J.D. (Age 60)Chief Financial Officer Comp: $523.38kKey CompetitorsINVO BioscienceNASDAQ:INVOTenon MedicalNASDAQ:TNONAssureNASDAQ:IONMAethlon MedicalNASDAQ:AEMDDynatronicsNASDAQ:DYNTView All Competitors QNRX Stock Analysis - Frequently Asked Questions Should I buy or sell Quoin Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QNRX shares. View QNRX analyst ratings or view top-rated stocks. What is Quoin Pharmaceuticals' stock price target for 2024? 1 analysts have issued 12 month price targets for Quoin Pharmaceuticals' stock. Their QNRX share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 417.7% from the stock's current price. View analysts price targets for QNRX or view top-rated stocks among Wall Street analysts. How have QNRX shares performed in 2024? Quoin Pharmaceuticals' stock was trading at $4.91 on January 1st, 2024. Since then, QNRX stock has decreased by 84.3% and is now trading at $0.7727. View the best growth stocks for 2024 here. When is Quoin Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our QNRX earnings forecast. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) announced its quarterly earnings results on Wednesday, March, 13th. The company reported ($2.08) earnings per share for the quarter, topping analysts' consensus estimates of ($2.37) by $0.29. When did Quoin Pharmaceuticals' stock split? Quoin Pharmaceuticals's stock reverse split on the morning of Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QNRX) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceGold ManiaStansberry ResearchShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
